These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group. Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236 [Abstract] [Full Text] [Related]
6. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Barnett A. Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841 [Abstract] [Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Herman GA, Stein PP, Thornberry NA, Wagner JA. Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725 [Abstract] [Full Text] [Related]
10. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Mathieu C, Bollaerts K. Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275 [Abstract] [Full Text] [Related]